Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: results from the open-label, randomised, phase II FRACTION-RCC trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

ESMO Open

Topics

Medicine

Cancer Oncology

Internal Medicine

Pulmonary And Respiratory Medicine

Economics And Econometrics

Show all topics

DOI

10.1016/j.esmoop.2024.104073

License

CC-BY-NC-ND